Hunter Gillies M.D.
Net Worth

Last updated:

What is Hunter Gillies M.D. net worth?

The estimated net worth of Mr. Hunter Gillies M.D. is at least $1,690,603 as of 17 May 2024. He owns shares worth $15,013 as insider, has earned $950,890 from insider trading and has received compensation worth at least $724,700 in Aerovate Therapeutics, Inc..

What is the salary of Hunter Gillies M.D.?

Mr. Hunter Gillies M.D. salary is $362,350 per year as Chief Medical Officer in Aerovate Therapeutics, Inc..

How old is Hunter Gillies M.D.?

Mr. Hunter Gillies M.D. is 59 years old, born in 1966.

What stocks does Hunter Gillies M.D. currently own?

As insider, Mr. Hunter Gillies M.D. owns shares in one company:

Company Title Shares Price per share Total value
Aerovate Therapeutics, Inc. (AVTE) Chief Medical Officer 5,602 $2.68 $15,013

What does Aerovate Therapeutics, Inc. do?

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE logo
AVTE
Aerovate Therapeutics, Inc.
$2.68

Hunter Gillies M.D. insider trading

Aerovate Therapeutics, Inc.

Mr. Hunter Gillies M.D. has made 12 insider trades between 2023-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 9,000 units of AVTE stock on 28 Mar 2024. As of 17 May 2024 he still owns at least 5,602 units of AVTE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 4,000 $2.14 $8,560
Option
Common Stock 4,000 $2.14 $8,560
Sale
Common Stock 3,914 $21.07 $82,452
Sale
Common Stock 86 $21.86 $1,880
Option
Stock Option (Right to Buy) 3,497 $1.74 $6,085
Option
Stock Option (Right to Buy) 503 $1.74 $875
Option
Common Stock 4,000 $1.74 $6,960
Sale
Common Stock 311 $23.33 $7,255
Sale
Common Stock 3,689 $22.3 $82,268
Sale
Common Stock 9,000 $29.5 $265,500
Option
Stock Option (Right to Buy) 9,000 $2.14 $19,260
Option
Common Stock 9,000 $2.14 $19,260
Sale
Common Stock 6,387 $25.81 $164,874
Option
Stock Option (Right to Buy) 4,000 $1.74 $6,960
Option
Common Stock 3,000 $2.14 $6,420
Option
Stock Option (Right to Buy) 3,000 $2.14 $6,420
Sale
Common Stock 613 $26.4 $16,184
Option
Common Stock 4,000 $1.74 $6,960
Option
Stock Option (Right to Buy) 945 $2.14 $2,022
Sale
Common Stock 8,975 $24.5 $219,888
Option
Common Stock 8,975 $2.14 $19,207
Option
Stock Option (Right to Buy) 8,030 $2.14 $17,184
Sale
Common Stock 511 $19.5 $9,965
Option
Stock Option (Right to Buy) 511 $1.74 $889
Option
Common Stock 511 $1.74 $889
Option
Stock Option (Right to Buy) 987 $1.74 $1,717
Option
Stock Option (Right to Buy) 65 $1.74 $113
Sale
Common Stock 65 $19.5 $1,268
Option
Common Stock 65 $1.74 $113
Sale
Common Stock 1,090 $19.59 $21,356
Option
Stock Option (Right to Buy) 1,090 $1.74 $1,897
Option
Common Stock 1,090 $1.74 $1,897
Sale
Common Stock 4,000 $19.5 $78,000
Option
Stock Option (Right to Buy) 4,000 $1.74 $6,960
Option
Common Stock 4,000 $1.74 $6,960

Aerovate Therapeutics key executives

Aerovate Therapeutics, Inc. executives and other stock owners filed with the SEC: